Methylation cluster risk membership retains prognostic significance by multivariate analysis
| . | . | Univariable . | Multivariable . | ||
|---|---|---|---|---|---|
| . | n (%) . | HR (95% CI) . | P* . | HR (95% CI) . | P* . |
| Model 1: Clinical features and cluster risk retained by multivariable analysis | |||||
| Cluster risk group | |||||
| High vs low | 52 (48) | 1.95 (1.24-3.08) | .003 | 2.02 (1.25-3.27) | .004 |
| Clinical features | |||||
| Karyotype | .13 | ||||
| Abnormal (not complex) vs normal | 33 (31) | 1.35 (0.82-2.24) | .24 | 1.43 (0.85-2.39) | .174 |
| Complex vs normal | 9 (8) | 2.20 (0.93-5.20) | .071 | 2.79 (1.15-6.75) | .023 |
| Bone marrow blasts, % | .014 | ||||
| 5-10 vs <5 | 23 (21) | 2.14 (1.22-3.77) | .008 | 2.18 (1.23-3.86) | .007 |
| 11-30 vs <5 | 23 (21) | 1.77 (1.01-3.09) | .046 | 1.40 (0.79-2.49) | .252 |
| Model 2: Clinical features, somatic mutations, and cluster risk retained by multivariable analysis | |||||
| Cluster risk group | |||||
| High vs low | 52 (48) | 1.95 (1.24-3.08) | .003 | 1.60 (0.95-2.71) | .076 |
| Clinical features | |||||
| Karyotype | .13 | ||||
| Abnormal (not complex) vs normal | 33 (31) | 1.35 (0.82-2.24) | .24 | 1.30 (0.75-2.28) | .353 |
| Complex vs normal | 9 (8) | 2.20 (0.93-5.20) | .071 | 2.91 (1.16-7.28) | .022 |
| Bone marrow blasts, % | .014 | ||||
| 5-10 vs <5 | 23 (21) | 2.14 (1.22-3.77) | .008 | 2.08 (1.16-3.73) | .014 |
| 11-30 vs <5 | 23 (21) | 1.77 (1.01-3.09) | .046 | 1.55 (0.85-2.83) | .15 |
| Somatic mutations | |||||
| RUNX1 mutated vs not mutated | 19 (18) | 2.12 (1.22-3.68) | .008 | 1.97 (1.07-3.64) | .031 |
| EZH2 mutated vs not mutated | 9 (8) | 2.91 (1.37-6.18) | .005 | 2.19 (0.91-5.24) | .079 |
| TP53 mutated vs not mutated | 9 (8) | 3.16 (1.41-7.08) | .005 | 2.40 (0.96-6.01) | .062 |
| . | . | Univariable . | Multivariable . | ||
|---|---|---|---|---|---|
| . | n (%) . | HR (95% CI) . | P* . | HR (95% CI) . | P* . |
| Model 1: Clinical features and cluster risk retained by multivariable analysis | |||||
| Cluster risk group | |||||
| High vs low | 52 (48) | 1.95 (1.24-3.08) | .003 | 2.02 (1.25-3.27) | .004 |
| Clinical features | |||||
| Karyotype | .13 | ||||
| Abnormal (not complex) vs normal | 33 (31) | 1.35 (0.82-2.24) | .24 | 1.43 (0.85-2.39) | .174 |
| Complex vs normal | 9 (8) | 2.20 (0.93-5.20) | .071 | 2.79 (1.15-6.75) | .023 |
| Bone marrow blasts, % | .014 | ||||
| 5-10 vs <5 | 23 (21) | 2.14 (1.22-3.77) | .008 | 2.18 (1.23-3.86) | .007 |
| 11-30 vs <5 | 23 (21) | 1.77 (1.01-3.09) | .046 | 1.40 (0.79-2.49) | .252 |
| Model 2: Clinical features, somatic mutations, and cluster risk retained by multivariable analysis | |||||
| Cluster risk group | |||||
| High vs low | 52 (48) | 1.95 (1.24-3.08) | .003 | 1.60 (0.95-2.71) | .076 |
| Clinical features | |||||
| Karyotype | .13 | ||||
| Abnormal (not complex) vs normal | 33 (31) | 1.35 (0.82-2.24) | .24 | 1.30 (0.75-2.28) | .353 |
| Complex vs normal | 9 (8) | 2.20 (0.93-5.20) | .071 | 2.91 (1.16-7.28) | .022 |
| Bone marrow blasts, % | .014 | ||||
| 5-10 vs <5 | 23 (21) | 2.14 (1.22-3.77) | .008 | 2.08 (1.16-3.73) | .014 |
| 11-30 vs <5 | 23 (21) | 1.77 (1.01-3.09) | .046 | 1.55 (0.85-2.83) | .15 |
| Somatic mutations | |||||
| RUNX1 mutated vs not mutated | 19 (18) | 2.12 (1.22-3.68) | .008 | 1.97 (1.07-3.64) | .031 |
| EZH2 mutated vs not mutated | 9 (8) | 2.91 (1.37-6.18) | .005 | 2.19 (0.91-5.24) | .079 |
| TP53 mutated vs not mutated | 9 (8) | 3.16 (1.41-7.08) | .005 | 2.40 (0.96-6.01) | .062 |
P values for individual categories within variables were calculated using the Wald test. P values for full variables correspond to a log-rank test. Multivariable models were constructed by optimizing the Aikake Information Criterion, which is why some multivariable P values are <.05.